Study points to possible treatment target for aggressive liver cancer in kids

June 11, 2018, Cincinnati Children's Hospital Medical Center

A protein in the cell nucleus already targeted therapeutically for several types of cancer has now been linked to an aggressive form of pediatric liver cancer called hepatoblastoma (HBL), according to a study published in the Nature journal Communications Biology.

Scientists at Cincinnati Children's Hospital Medical Center conducted extensive biological and genetic tests on donated HBL tumor samples and found highly elevated levels of the protein PARP1 in patients with this cancer. PARP1 modifies chromatin structure in the to drive the chemotherapy-resistant form of liver cancer, according to the study's lead investigator, Nikolai Timchenko, Ph.D., head of the Liver Tumor Biology, Liver Tumor Program.

An FDA-approved drug called Olaparib that blocks PARP1 is already used to treat other types of cancer. In their tests on human liver , Timchenko and colleagues learned that PARP1 binds to DNA regions within many cancer-related genes and activates their expression in (HBL) to drive the disease. When the researchers pharmacologically blocked PARP1 in the tumor cells, this slowed or stopped cancer progression.

"Our findings provide a strong rationale for testing PARP1 inhibitors to treat aggressive pediatric liver cancer, but additional research is needed before we can verify this and recommend that it be tried in patients," Timchenko said. "This includes testing inhibitors in laboratory mouse models of hepatoblastoma to see if they work in a living organism."

The researchers also caution that findings in laboratory models often are not effective in the clinical treatment of patients.

Most Common Pediatric Liver Cancer

HBL is the most common type of pediatric cancer and affects children during the first three years of life. Although overall survival rates for these patients have improved over the years, substantial numbers of them see their cancer spread, or they face aggressive, therapy-resistant tumors that cannot be removed surgically.

Children with the classic form of HBL have reduced levels of (TSPs). The researchers report that patients with aggressive disease have elevated levels of TSPs which undergo modifications and display cancer-promoting (oncogenic) activities. PARP1 is the molecule that causes elevation of the oncogenic forms of the TSPs in aggressive hepatoblastoma as well as activation of other -related pathways such as beta-catenin.

Explore further: Identifying a new type of liver tumor

More information: Leila Valanejad et al, PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma, Communications Biology (2018). DOI: 10.1038/s42003-018-0077-8

Related Stories

Identifying a new type of liver tumor

August 9, 2017
Investigators at Children's Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease—a necessary step in achieving an optimum treatment.

A way to prevent pancreatic cancer from spreading post-surgery?

May 17, 2018
Scientists at Cold Spring Harbor Laboratory (CSHL) have solved a mystery about how pancreatic cancer spreads following surgery in patients whose tumor is successfully removed. After surgery, patients' typically experience ...

Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug

May 10, 2018
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors.

Liver cancer caused by alcohol consumption may have worse prognosis than other forms

March 28, 2018
A new study indicates that patients with alcohol-related liver cancer often do not live as long as patients with liver cancer that is not associated with alcohol consumption, mainly due to diagnoses at later stages. Published ...

Scientists take early step to personalized breast cancer care

November 29, 2017
UT Southwestern Medical Center researchers have developed a method to map protein changes that occur in different subtypes of breast cancer cells in response to DNA damage from a new class of chemotherapy drugs.

Study shows increase in liver transplantation for hepatoblastoma

March 5, 2013
Liver transplantation for hepatoblastoma, the most common liver malignancy in children, is on the rise because more tumors are being detected earlier, improving outcomes for these sick patients, according to a Children's ...

Recommended for you

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.